PI

Zesong Li

Full-time Principal Investigator (PI), Ph.D. Advisor, and Postdoctoral Co-advisor

Email：lzssc@email.szu.edu.cn

PI介绍

Ph.D., Researcher, Full-time Principal Investigator (PI), Ph.D. Advisor, and Postdoctoral Co-advisor. High-Level Talent of Shenzhen (Peacock Plan B). Executive Director of the Guangdong Provincial Key Laboratory of Urogenital Tumor System and Synthetic Biology, Director of the Shenzhen Key Laboratory of Urogenital Tumor Research. Vice President of the Shenzhen Association of Life Sciences and Technology, Vice President of the Shenzhen Thalassemia Prevention and Treatment Association, and Director of the Shenzhen In Vitro Diagnostics Alliance. Expert reviewer for key projects under the National Key R&D Program, major international cooperation projects, National Science and Technology Innovation Leading Talent Program, National High-Level Talent Special Support Program, and National Natural Science Foundation of China. Peer reviewer for journals such as Cancer Research, Biomedicine & Pharmacotherapy, and Free Radical Biology and Medicine. Principal investigator for three National Natural Science Foundation of China general projects. Published 74 papers in SCI journals including Nature Genetics, American Journal of Hematology, Cell Death & Disease, and Cancer Letters. Holder of two authorized invention patents. As the primary contributor, obtained one national new drug certificate, with cumulative sales exceeding 80 million RMB.

教育背景

Education:

September 1986 - July 1990:Bachelor of Biology, School of Life Sciences, Southwest University

September 1997 - July 2000:Master of Biochemistry and Molecular Biology, School of Life Sciences, Wuhan University

March 2006 - December 2008:Ph.D. in Biomedical Engineering, College of Biomedical Engineering, Chongqing University

工作经历

August 1990 - August 1997:Teacher at Jincheng Middle School, Xichong County, Sichuan Province

August 2000 - March 2001:Research Intern at Xinghai Technology Co., Ltd., Zhaoqing City, Guangdong Province

March 2001 - December 2006:Engineer, Assistant Researcher, Manager at Shenzhen Yishengtang Biotech Company

December 2006 - December 2008:Research Associate, Faculty of Medicine, The University of Hong Kong

January 2009 - April 2011:Postdoctoral Fellow, Associate Researcher at Shenzhen Peking University - Hong Kong University of Science and Technology Medical Center

May 2011 - September 2013:Associate Researcher, Deputy Director at Shenzhen Second People's Hospital

May 2012 - Present:Director of the Shenzhen Key Laboratory of Urogenital Tumor Research

October 2013 - October 2017:Deputy Director, Associate Researcher at the Central Laboratory of Shenzhen Second People's Hospital

August 2017 - Present:Executive Director of the Guangdong Provincial Key Laboratory of Urogenital Tumor System and Synthetic Biology

April 2019 - Present:Deputy Director and Principal Investigator (PI), Researcher at Shenzhen Institute of Translational Medicine, Shenzhen Second People's Hospital

研究方向和兴趣

(1) Tumor Molecular Biology: Utilizing multi-omics technologies to identify new protein-coding genes, long non-coding RNAs, and circular DNAs associated with urological tumors. Investigating their biological functions and roles in tumor development and progression, along with underlying molecular mechanisms, using cell models and gene knockout mouse models.

(2) Tumor Translational Medicine: Employing the latest proximity coding detection technology to identify urinary exosome protein biomarkers in patients with urogenital tumors and developing corresponding diagnostic reagents. Using DNA-encoded compound library drug screening combined with PDX models to identify small molecule drugs targeting tumors.

科研项目

Shenzhen Municipal Science and Technology Innovation Committee Key Laboratory Construction Plan: Shenzhen Key Laboratory of Urogenital Tumor (Project No.: CXB201111240107A), Principal Investigator, 2012-2014, 5 million RMB. Completed.

National Natural Science Foundation of China (NSFC) General Project: Study on the Relationship between C12orf59 Gene and Renal Cell Carcinoma (Project No.: 81272840), Principal Investigator, 2013-2016, 760,000 RMB. Completed.

National Natural Science Foundation of China (NSFC) General Project: Expression, Regulation, and Biological Functions of Novel Gene C8orf84 in Bladder Cancer (Project No.: 81472584), Principal Investigator, 2015-2018, 750,000 RMB. Completed.

National Natural Science Foundation of China (NSFC) General Project: Molecular Mechanism Study of Expression and Functional Differences of TMEM52B Gene Splice Isoforms in Renal Cell Carcinoma (Project No.: 81972366), Principal Investigator, 2020-2023, 550,000 RMB. Ongoing.

Shenzhen Municipal Science and Technology Innovation Committee Major Special Project: Development of Early Screening Reagent Kit for Diabetic Neurogenic Bladder (Project No.: 202110203002406), Principal Investigator, 2022-2024, 2 million RMB. Ongoing.

Shenzhen Municipal Science and Technology Innovation Committee Major Special Project: Research on Molecular Immunological Mechanisms in the Development of Diseases (Project No.: JCYJ20220818101808018), Principal Investigator, 2023-2025, 1.5 million RMB. Ongoing.

代表性成果

[1]Li Z^§, Guo R, Zhang W. Rapid detection of deletional α-thalassemia by an oligonucleotide microarray. Am J Hematol 2005; 80:306-308

[2]Li Z, Chen J, Chan KW, Qiao L, Wong BC. A possible role of cIAP2 in helicobacter pylori-associated gastric cancer. Cancer Lett 2011; 313: 192-200

[3]Guo G*, Sun X*, Chen C*, Wu S*, Huang P*, Li Z*, Dean M*, Huang Y, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;15:1459-1463

[4]Xie X*, Lin J*, Fan X*, Zhong Y, Chen Y, Liu K, Ren Y, Chen X, Lai D, Li X, Li Z^§, Tang A^§. LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription. Cell Death Dis 2021;12(2):201

[5]Lin J*, Chen X*, Yu H, Min S, Chen Y, Li Z^§, Xie X^§. NUF2 Drives Clear Cell Renal Cell Carcinoma by Activating HMGA2 Transcription through KDM2A-mediated H3K36me2 Demethylation. Int J Biol Sci 2022; 18(9): 3621-3635

科研团队

Associate Researcher: Xie Xi'na

Technicians: Li Shi, Mao Longyi, Zhang Wanqing, Yu Ziyi, Min Shasha

Postdoctoral Fellows (completed their tenure with National Natural Science Foundation funding): Diao Ruiying, Gao Hanchao, Liu Wei, Ni Beibei, Cai Yanling, Lu Yanxin, Xu Chunhua

Current Postdoctoral Fellows: Zhu Yuqi, Yang Wei, Zhang Yu

Ph.D. Student: Zaara Liaquat

Master's Students (graduated): Luo Liya, Xia Lingling, Liu Yang, Zhou Feng